#United States #Spartanburg #AccessDx Laboratory #pharmacogenomics #Spartanburg Regional

Spartanburg Regional Healthcare System Enhances Patient Care Through Strategic Partnership

In a groundbreaking move towards improving personalized healthcare, Spartanburg Regional Healthcare System (SRHS) has forged a partnership with AccessDx Laboratory to launch a comprehensive pharmacogenomics (PGx) program. This initiative is set to provide invaluable insights into how patients metabolize medications, ultimately leading to more effective treatment outcomes and reduced risks associated with drug-gene interactions.

Understanding Pharmacogenomics

Pharmacogenomics is the study of how genes affect a person’s response to drugs. By understanding these genetic factors, clinicians can tailor treatment plans that enhance effectiveness while minimizing the risks of adverse drug reactions. SRHS aims to implement PGx testing for both their patients and employees, ensuring that every individual receives personalized care throughout their medical journey.

The Role of AccessDx Laboratory

Selected for their high standards and commitment to health equity, AccessDx Laboratory brings a wealth of expertise to this collaboration. The laboratory utilizes comprehensive multispecialty panels to analyze rare genetic variants, all while integrating lab results seamlessly into electronic health records (EHR). According to Bryon Cipriani, CEO of AccessDx Laboratory, this partnership enhances SRHS’s capacity to optimize patient care significantly.

“PGx testing is vital for patients throughout their care paths. Our partnership emphasizes the importance of precision medicine across various healthcare disciplines,” said Cipriani. This approach empowers healthcare providers to deliver insights and educational resources that further elevate patient care.

Education and Training for Effective Implementation

As part of this initiative, SRHS plans to leverage AccessDx Laboratory's expertise to educate clinicians and care teams. This includes developing expert content and training programs designed to equip healthcare providers with the knowledge needed to implement PGx testing effectively. Charles Morrow, MD, Executive Vice President and Chief Operating Officer at SRHS, expressed enthusiasm for the partnership, emphasizing how this program will enable clinicians to provide superior care locally without requiring patients to travel outside their community for specialized treatment.

Targeted Areas of Implementation

The launch of the PGx program will begin in key clinical areas such as family practice, oncology, maternal-fetal medicine, behavioral health, and pediatrics. By 2025, SRHS aims to expand PGx testing availability across all clinical specialties. This initiative is part of a broader strategy focusing on precision medicine, aiming to incorporate drug-gene insights in various facets of patient care.

Commitment to Health Equity

Both SRHS and AccessDx Laboratory share a deep commitment to advancing health equity and improving patient outcomes. The partnership is designed to ensure that all community members can access impactful, precision medicine-based treatments within their local healthcare settings. The goal is to demystify pharmacogenomics and make it a standard aspect of care that enhances treatment decisions.

As SRHS implements these advancements, it positions itself at the forefront of the healthcare industry's shift toward precision medicine. Through collaboration, innovation, and education, both organizations are setting new standards for community health and patient-centered care.